Gilead Sciences (GILD) call put ratio 2.3 calls to 1 put after FT says remdesivir failed in first trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. NKE
10. PRIM

Go back to Gilead Sciences (GILD) call put ratio 2.3 calls to 1 put after FT says remdesivir failed in first trial

WHO China Data Likely to Drive View that Gilead (GILD) Remdesivir Isn't Working in Severe Patients - Raymond James

April 23, 2020 2:00 PM EDT

Raymond James analyst Steven Seedhouse weighed in on Gilead Sciences (NASDAQ: GILD) related to news that a China trial of severe patients showed remdesivir didn't improve patients' condition.

"GILD's immediate response seems to be that the Chinese data do not enable statistically meaningful... More

Gilead Sciences (GILD) China Trial Results 'In Line with our Expectations' - RBC

April 23, 2020 1:40 PM EDT

RBC Capital analyst Brian Abrahams weighed in on Gilead Sciences (NASDAQ: GILD) related to news that a China trial of severe patients showed remdesivir didn't improve patients' condition.

"If this is ultimately confirmed, this would be completely in line with our... More

Gilead Sciences (GILD) Remdesivir China Results 'Very Sobering' - Baird

April 23, 2020 1:34 PM EDT

Baird analyst Brian Skorney weighed in on Gilead Sciences (NASDAQ: GILD) related to news that a China trial of severe patients showed remdesivir didn't improve patients' condition.

Skorney commented, "This afternoon, an abstract leaked indicating that Gilead's remdesivir failed to provide a benefit... More